Effects of Etanercept Combined with Cyclophosphamide on Related Indexes of Rheumatoid Arthritis Patients with Interstitial Pneumonia
10.6039/j.issn.1001-0408.2018.02.22
- VernacularTitle:依那西普联合环磷酰胺对类风湿性关节炎合并间质性肺炎患者相关指标的影响
- Author:
Liangmin CHEN
1
;
Yong JIANG
;
Lijuan XING
;
Zhihua CHU
;
Jin GAO
Author Information
1. 解放军第59中心医院肾内风湿免疫科
- Keywords:
Rheumatoid arthritis;
Interstitial pneumonia;
Etanercept;
Cyclophosphamide;
Lung function;
Life quality;
Safety
- From:
China Pharmacy
2018;29(2):236-240
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the effects of etanercept combined with cyclophosphamide on related indexes of patients with rheumatoid arthritis complicated with interstitial pneumonia (RA-IP).METHODS:A total of 84 RA-IP patients were randomly divided into control group (42 cases) and observation group (42 cases).Control group was given Etanercept for injection 25 mg subcutaneously twice a day.Observation group was additionally given Cyclophosphamide tablets 50 mg orally,once a day,increasing by 50 mg every 7 d later,with maximum dose lower than 100 mg,for consecutive 2 weeks,2 weeks later repeated,on the basis of control group.Both groups were treated for 3 months.The number of joint tenderness and joint swelling,morning stiffness time,VAS score,DAS28 score,CRP,ESR,serum rheumatoid factor (RF),TNF-α,p (O2),VC,clinical score,imaging score,physiological score and the occurrence of ADR were observed in 2 groups before and after treatment.RESULTS:After treatment,the number of joint tenderness and joint swelling,morning stitffness time,VAS score,DAS28 score,the levels of CRP,ESR,RF and TNF-α,clinical score,imaging score,physiological score in 2 groups were significantly lower than before treatment;the observation group was significantly lower than control group.p(O2) and VC of 2 groups were significantly higher than before treatment,and the observation group was significantly higher than the control group,with statistical significance (P＜0.05).There was no statistical significance in the incidence of ADR between 2 groups (P＞0.05).CONCLUSIONS:Etanercept combined with cyclophophamide in the treatment of RA-IP can improve clinical symptom,signs,life quality and lung function without increasing the occurrence of ADR.
